A detailed history of Bristlecone Advisors, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Bristlecone Advisors, LLC holds 2,150 shares of VRTX stock, worth $998,804. This represents 0.08% of its overall portfolio holdings.

Number of Shares
2,150
Previous 2,150 -0.0%
Holding current value
$998,804
Previous $1.01 Million 0.79%
% of portfolio
0.08%
Previous 0.09%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 25, 2024

SELL
$392.81 - $485.53 $5,892 - $7,282
-15 Reduced 0.69%
2,150 $1.01 Million
Q1 2024

Apr 22, 2024

BUY
$407.69 - $446.08 $46,884 - $51,299
115 Added 5.61%
2,165 $904,000
Q4 2023

Jan 25, 2024

BUY
$343.0 - $410.68 $1,715 - $2,053
5 Added 0.24%
2,050 $834,000
Q3 2023

Oct 16, 2023

SELL
$338.18 - $362.46 $18,938 - $20,297
-56 Reduced 2.67%
2,045 $711,000
Q2 2023

Aug 03, 2023

SELL
$314.42 - $351.91 $18,236 - $20,410
-58 Reduced 2.69%
2,101 $739,000
Q1 2023

May 11, 2023

SELL
$283.23 - $323.1 $92,332 - $105,330
-326 Reduced 13.12%
2,159 $680,000
Q4 2022

Feb 14, 2023

SELL
$285.76 - $321.48 $14,573 - $16,395
-51 Reduced 2.01%
2,485 $717,000
Q3 2022

Oct 27, 2022

SELL
$273.83 - $305.53 $7,941 - $8,860
-29 Reduced 1.13%
2,536 $734,000
Q2 2022

Jul 25, 2022

BUY
$234.96 - $292.55 $70,957 - $88,350
302 Added 13.35%
2,565 $723,000
Q1 2022

Apr 22, 2022

BUY
$221.42 - $260.97 $5,314 - $6,263
24 Added 1.07%
2,263 $591,000
Q4 2021

Jan 19, 2022

BUY
$177.01 - $223.45 $48,500 - $61,225
274 Added 13.94%
2,239 $492,000
Q3 2021

Oct 19, 2021

BUY
$181.39 - $202.99 $74,369 - $83,225
410 Added 26.37%
1,965 $356,000
Q2 2021

Jul 21, 2021

BUY
$187.49 - $221.1 $3,937 - $4,643
21 Added 1.37%
1,555 $314,000
Q1 2021

Apr 30, 2021

BUY
$207.02 - $241.31 $35,400 - $41,264
171 Added 12.55%
1,534 $330,000
Q4 2020

Jan 25, 2021

BUY
$207.01 - $276.09 $282,154 - $376,310
1,363 New
1,363 $322,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $119B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Bristlecone Advisors, LLC Portfolio

Follow Bristlecone Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bristlecone Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bristlecone Advisors, LLC with notifications on news.